" class="no-js "lang="en-US"> Dan Howarth - Medtech Alert
Tuesday, September 02, 2025

Breaking News

Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Astellas and Cullgen Enter into Strategic Collaboration and Option Agreement to Advance Innovative Targeted Protein Degraders Auxilius Pharma Raises Seed Funding of $1 Million and Commences its Clinical Program Captivate Bio and EverCell Bio partner on Human Cell Modeling Services for Cell and Gene Therapy Markets Applied StemCell Partners with CIRM to Provide Clinical-Grade iPSCs and Access to Its Proprietary Gene Editing Technologies Alentis Therapeutics Receives IND Clearance from FDA for ALE.C04 for the Treatment of CLDN1+ Tumors
Dan Howarth

Dan Howarth

About Dan Howarth

Empathetic diabetes specialist nurse consultant. Sub speciality in insulin management and emergency diabetes care. Experience at service development and working within low and middle income countries. Passionate about high quality care for all people with diabetes Has a unique ability to educate others. An infectious enthusiasm, patient focused and highly skilled communicator within an autonomous and team setting.

Related Story

Diseases

 NHS to Diagnose Thousands of People with Rare Diabetes | Pharmtech Focus

NHS to Diagnose Thousands of People with Rare Diabetes

August 31 2021

Genetic testing on the NHS will spot a rare form of diabetes in thousands of […]